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When introducing multiplex platforms to measure protein content in precious clinical mate-
rial  there is an increased risk of cross reactivity, loss of sensitivity as well as accuracy. In this
paper, four multiplex platforms and one singleplex platform were compared by running pre-
and post-treatment plasma samples from CML patients. We  found a variation of absolute
protein concentrations between platforms. For some of the analytes and platforms, relative
differences between pre- and post-treatment samples correlated. We conclude that abso-
lute  concentrations measured by different platforms should be compared with caution andLISA
uminex
omalogic
eso Scale Discovery
hronic myeloid leukemia
comparing relative differences could be more accurate.
©  2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). 
samples such as human plasma or serum is becoming increas-
Open access under CC BY-NC-ND license.igniﬁcance
oday many  research groups select a multiplex platform for
heir clinical research investigations based on the current
vailability of a certain machine in-house. Clinical material
s usually scars and can rarely be used to explore intra- or
nter assay variations with regard to absolute or relative pro-
ein concentrations; still the material as well as the assay can
ffect the results obtained. Herein we  had an unique possibil-
ty to obtain and analyze clinical material from CML patients
re- and post TKI therapy to assess inﬂammatory patterns
∗ Corresponding author at: Uppsala University, Dag Hammarskjölds väg
E-mail  address: sara.mangsbo@igp.uu.se (S.M. Mangsbo).
ttp://dx.doi.org/10.1016/j.euprot.2014.02.002
212-9685 © 2014 The Authors. Published by Elsevier B.V. on behalf ofusing a plethora of assays in order to investigate how absolute
and relative protein concentrations correlate between these
platforms.
1.  Introduction
The possibility of multiplex protein analysis in complex 20, 75185 Uppsala, Sweden. Tel.: +46 186119181.
ingly important and the multiplexed platforms are used in
for example clinical diagnostics; biomarker validation; mea-
surement of changes in protein abundance and modeling
 European Proteomics Association (EuPA). Open access under CC BY-NC-ND license.
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networks, and measurement of pathways in physiological and
disease states [1]. Multiplex protein quantiﬁcation sets new
and high demands on speciﬁcity of the detection reagents as
well as buffers and other reagents used, as various targets
may require different conditions for optimal quantiﬁcation
[2]. Consequently, multiplex assays require high levels of vali-
dation to ensure that the targets are detected optimally and
with high speciﬁcity. Vignali has deﬁned seven key parameters
for creating a perfect multiplexed assay including speciﬁcity,
sensitivity, simplicity, reliability, multiplexing abilities, cost
and time [3].
Dependent on the application of the assay, some of these
parameters may be more  important than others. Additionally,
certain patient material may affect assay results, requiring
both the platform producer and the user to carefully eval-
uate data output with respect to the selected material. In
this paper, we  have investigated four different multiplex plat-
forms for protein measurements and compared the results to
results obtained from the golden standard of soluble protein
quantiﬁcation, the ELISA. Three of the multiplex platforms
investigated (BioPlex, Meso Scale Discovery and Myriad RBM)
as well as the ELISAs determine the absolute concentration
of protein in the samples, while one platform (Somalogic) is
designed as a discovery platform and measures only relative
concentrations of protein.
The three multiplex platforms used for quantitative deter-
mination of proteins are, similar to ELISA, immunoassays
where analytes are “sandwiched” between a capture- and a
detection antibody before detection [2]. In a common single-
plex ELISA the detection antibody is usually conjugated to an
enzyme, that after the addition of enzyme substrate cataly-
ses a reaction leading to color development in the microtiter
plate. The intensity of the color is measured by spectropho-
tometry and corresponds to the amount of the speciﬁc protein
to be detected in the unknown sample [4]. Another method,
developed by Meso Scale Discovery, applies electrochemilu-
minescence to quantify the proteins in a microtiter plate [5].
This assay can be multiplexed since capture antibodies spe-
ciﬁc for different targets can be bound to distinct spots in
the bottom of a microtiter plate. In the microsphere-based
technology developed by Luminex Corporation, the Fc-parts
of the capture antibodies are bound to groups of ﬂuorescent
microspheres. Each group of microspheres has slightly dif-
ferent ﬂuorescence intensity and is covered with antibodies
recognizing a distinct protein. The detection antibody is cou-
pled to a ﬂuorescent molecule to enable detection [2]. With
the Luminex method two systems to quantify the level of pro-
tein are available. One of the systems, applied by Myriad RBM
in this paper, is ﬂow-based [6]. The other microsphere-based
system utilizes magnetic ﬂuorescent beads and is used by the
BioPlex kit in this paper [7]. The methods described in this
paper have different abilities of multiplexing, Meso Scale Dis-
covery kits are available with up to 10 different analytes [8]
while the Luminex technology can assay up to 50 analytes
with the magnetic beads and up to 500 analytes with the ﬂow
technology [9].Somalogic has developed a multiplex method for rel-
ative protein quantiﬁcation of up to over 1100 analytes
in one sample [10]. This technique is based on aptamer
binding. Aptamers are folded, single-stranded, anionic s 3 ( 2 0 1 4 ) 37–47
oligonucleotides that can bind proteins with high speciﬁcity
and afﬁnity. Somalogic has developed Slow Off-rate Modiﬁed
Aptamers called SOMAmers, these are modiﬁed aptamers that
have a slower dissociation rate of the aptamer from its target
protein compared to normal aptamers [11].
In this study, characteristics of different multiplex protein
detection platforms and their ability to detect various proteins
were compared. Plasma from patients with chronic myeloid
leukemia (CML) before and after tyrosine kinase inhibitor (TKI)
treatment was investigated in the study. We  show that the
absolute protein concentration varied when measured by the
different platforms. However, fold changes in protein concen-
tration after TKI treatment correlated for certain, but not all,
analytes on some platforms.
2.  Materials  and  methods
2.1.  Patient  samples,  control  sample  and  sample
preparation
Frozen acid citrate plasma samples from patients with CML
at baseline (before treatment) and after three months of
treatment with imatinib (Gleevec, Novartis Pharmaceuticals,
Basel, Switzerland) or dasatinib (Spyrcel, Bristol-Myers Squibb,
New York, USA) were obtained from Helsinki University Cen-
tral Hospital. The study was conducted in accordance with
the Helsinki Declaration and was approved by the Regional
Research Ethics Committee. All patients gave their written
informed consent. Frozen samples were shipped to Uppsala,
thawed on ice and subsequently vortexed. Aliquots of appro-
priate volumes for each analysis were pipetted into different
tubes and refrozen at −70 ◦C. In each run a control sample
containing chicken plasma was included.
2.2.  BioPlex  Pro  Human  Cytokine  27-plex  Panel
Frozen plasma samples were thawed in 37 ◦C water bath and
put on ice directly after thawing. Samples were centrifuged at
10,000 × g for 10 min  prior to analysis to remove cell debris
and aggregates. BioPlex Pro Human Cytokine 27-plex Panel
(Bio-Rad Laboratories, Hercules CA, USA) analysis with Mag-
Plex beads was performed in a ﬂat bottom microtiter plate
according to the manufacture’s instructions. Brieﬂy, samples
were diluted 1:4 in sample diluent. Standard was reconstituted
and diluted in a fourfold dilution series. Antibody coupled
capture beads were prepared and plated. The bead solution
was vortexed before addition to each well. Plate was washed,
all wash steps were performed manually. First, wash solu-
tion was added to the plate that was subsequently covered
with sealing tape. The plate was incubated on a shaker for
30 s at 1100 rpm and then for 1.5 min  at 300 rpm. The plate
was  taken off the shaker and was incubated on a magnet for
1 min  before the supernatant was discarded. After washing,
diluted samples and standards were added in duplicates to the
beads in the wells. The plate was incubated on a shaker and
after incubation and wash, detection antibodies were added
to each well. The plate was again incubated on a shaker and
after another washing step, streptavidin-phycoerythin solu-
tion was added to the wells. After a last incubation step, beads
m i c s
w
w
w
a
t
s
w
c
u
i
2
c
E
w
a
c
s
w
t
d
w
b
s
r
w
A
t
t
a
t
U
v
c
c
w
t
2
k
C
c
S
b
w
u
t
b
c
t
c
a
D
p
o
a
b
ae u  p a o p e n p r o t e o 
ere resuspended in assay buffer and the plate was read
ith a MagPix (Luminex Corporation) using the xPONENT soft-
are (Luminex Corporation, Austin, TX, USA). The results were
nalyzed using the xPONENT software. The absolute concen-
rations of the samples were determined by construction of a
tandard curve for each analyte. Points in the standard curve
ith recovery below 70% or above 130% were invalidated and
urve ﬁt was made with a weighted 5PL method. In total, a vol-
me  of 30 l undiluted sample was used for running duplicate
n this assay.
.3.  Interferon  gamma  (IFN)  and  monocyte
hemotactic  protein-1  (MCP-1)  ELISA
LISAs for IFN and MCP-1 (BioLegend, San Jose, CA, USA)
ere run according to the manufacturers’ instructions. Brieﬂy,
ll components including frozen patient samples and control
hicken plasma were brought to room temperature. Patient
amples were spun at 10,000 × g for 5 min  where after they
ere diluted in assay buffer. Samples were diluted 1:2 for
he IFN ELISA and 1:4 for the MCP-1 ELISA. Standards were
iluted in a twofold dilution series. Standard and samples
ere added in duplicates to the wells containing capture anti-
odies. For duplicate wells, the total volume of undiluted
ample used for MCP-1 and IFN ELISAs was 30 l and 55 l,
espectively. After incubation and wash, detection antibody
as added. The plate was incubated and after another wash
vidin-HRP solution was added to the wells. After incubation,
he plate was washed and substrate solution was added to
he wells. Following a last incubation step, stop solution was
dded to the plate and the absorbance was read at 450 nm with
he Emax ELISA reader (Molecular Devices LLC, Sunnyvale, CA,
SA). The 570 nm absorbance was subtracted from the 450 nm
alue. SoftMax 2.35 software (Molecular Devices) was used for
onstruction of standard curves and determination of protein
oncentration in unknown samples. Curve ﬁtting was done
ith a 4PL algorithm according to the manufacturer’s instruc-
ions.
.4.  Human  proinﬂammatory  9-plex  Ultra-Sensitive
it
ryopreserved plasma and control samples as well as all kit
omponents from the Human proinﬂammatory 9-plex Ultra-
ensitive kit (Meso Scale Discovery, Rockville, MD, USA) were
rought to room temperature before analysis. The analysis
as performed according to the instructions from the man-
facturer. Reverse pipetting was applied in all pipetting steps
o avoid bubbles. Brieﬂy, the antibody coated plate was incu-
ated with diluent for 30 min  on a shaker (800 rpm). The
alibrator containing known concentrations of all analytes
o be analyzed was diluted in a fourfold dilution series to
reate a standard curve. Patient plasma samples were spun
t 10,000 × g for 5 min  to remove cell debris and aggregates.
uplicates of diluted calibrator and undiluted plasma sam-
les were loaded on the plate and the plate was incubated
n a shaker for two  hours. After washing, labeled detection
ntibodies were pipetted to the wells and the plate was incu-
ated for another 2 h. After incubation the plate was washed
nd read buffer was added to the plate just before reading 3 ( 2 0 1 4 ) 37–47 39
in the SECTOR Imager 2400 (Meso Scale Discovery) using the
MSD  discovery workbench Software (Meso Scale Discovery).
Curve ﬁtting was done in the same software using a 4PL ﬁt
with 1/y2 weighting according to the manufacturer’s instruc-
tions and concentrations were determined from the standard
curves. For running duplicates in this assay, a total volume of
50 l undiluted sample was used.
2.5.  Multi-analyte  proﬁling  (MAP)  technology  by
Myriad  RBM
Tubes containing 100 l frozen aliquots from all patient sam-
ples and chicken plasma control sample were shipped to
Myriad RBM (Salt Lake City, UT, USA). Analysis of the cus-
tom human MAP containing 44 different analytes was run
according to the laboratory standard operating procedures
that involved automated pipetting. Samples were run in sin-
glet.
2.6.  SomaScan  by  Somalogic
Tubes containing 100 l frozen aliquots from all patient sam-
ples and chicken plasma control sample were shipped to
Somalogic (Boulder, CO, USA). 1129 analytes were analyzed in
the SomaScan according to the laboratory standard operating
procedures. Samples were run in singlet. Data were analyzed
using the SomaSuite software (Somalogic).
2.7.  Data  analysis
The percentage of samples in which protein concentrations
within the limits of quantiﬁcation could be detected was
depicted as % detectable samples for each analyte. After curve
ﬁtting and determination of absolute and relative concentra-
tions in respective software, mean- and max  fold changes
as well as pooled CV-values were calculated. The mean
fold change was calculated as the ratio between the mean
concentration at three months time point and the mean con-
centration at baseline. To determine the maximum (max) fold
change, fold changes for each individual patient was ﬁrst
calculated. Pooled coefﬁcient of variation (CV) values were
calculated by the formula:
CVpool =
√[
(CV21 + CV22, · · ·, CV2n)
n
]
where CV1, CV2, etc. represent CV-values obtained from each
sample, and n is the number of samples for which the pooled
CV is calculated.
Fold changes were only calculated for samples where both
of the duplicates were within the limits of quantiﬁcation and
CV-values were only included in the pooled CV-value if both
of the duplicates were within the limits of quantiﬁcation. To
be able to compare measurements of protein concentrations
in chicken plasma between all platforms, the ratio between
protein concentration in chicken plasma and the protein con-
centration in the patient sample with the lowest detectable
concentration of that particular analyte was calculated.
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2.8.  Statistical  analysis
For correlation of relative differences between different plat-
forms, the non-parametric Spearman correlation was applied.
To test whether or not fold changes were different between
platforms, the non-parametric unpaired Kruskal Wallis test
and Dunn’ post test was used when more  than two plat-
forms were compared. When two platforms were compared,
Wilcoxon matched-pairs signed rank test was applied.
3.  Results
3.1.  Platform  characteristics
In Table 1 characteristics of the different platforms are seen.
The speciﬁcity of the assays has been tested by most manu-
facturers, but information of which analytes that have been
tested for cross-reactivity was only available from the ELISA
manufacturer. The cost per data point was highest for the
ELISAs and lower for the multiplexed platforms. The Soma-
logic service had a high cost, but since a lot of analytes
were investigated at the same time the cost per data point
was much lower than for the other platforms. Protocols and
instructions from manufacturers were easy to follow except
for the BioPlex protocol that was sometimes problematic to
interpret. The time consumed for running the different proto-
cols in-house was between six and eight hours per kit.
3.2.  The  sensitivity  of  detection  varied  between
platforms  and  the  analyte  investigated
As shown in Table 2 and Supplementary Tables 1–5 the ability
to detect concentrations of investigated analytes in the sam-
ples, depicted as % detectable samples, varied between the
different platforms. Samples with concentrations within the
indicated limits of detection were considered detectable. MCP-
1 concentrations could be detected in most samples on all
different platforms investigated. IFN levels above background
was detected in all samples after analysis with the BioPlex
and Somalogic platforms but only in a few samples using the
ELISA, Meso Scale Discovery and Myriad RBM platforms. For
IL-8, the Meso Scale Discovery platform was more  sensitive
than BioPlex and Myriad RBM as protein concentrations could
be measured in all samples. For the Somalogic platform, no
limit of quantiﬁcation or detection was reported, hence, here
we report that all analytes could be detected in all samples.
Supplementary data associated with this article can
be found, in the online version, at doi:10.1016/j.euprot.
2014.02.002.
3.3.  CV  values  were  acceptable  for  most  analytes  on
all platforms  investigated
For the BioPlex, ELISA and Meso Scale Discovery duplicates
were run, hence, accuracy of these platforms could be reported
by the CV-value. From all CV-values within one run, a pooled
CV-value was calculated for each analyte. As seen in Table 2
and Supplementary Tables 1–3 the pooled CV-values were
acceptable, <15% for all analytes but three. The ELISA platform s 3 ( 2 0 1 4 ) 37–47
had pooled CV-values of 2.81–13.69% (Supplementary Table
2) and Meso Scale Discovery had pooled CV-values of
6.24–14.87% (Supplementary Table 3). For the BioPlex platform
all pooled CV-values but three were between 0.77 and 11.53%.
The IL-8 assay had a pooled CV-value of 13.86%, the IL-1ra
assay had a pooled CV-value of 32.38% and the G-CSF assay
had a pooled CV-value of 22.11% (Supplementary Table 1).
Somalogic reports a median %CV-value of 5.1% in plasma, this
value was based on a reproducibility experiments spanning 12
individuals, 3 assay plates, and different operators, however,
a CV-value for our speciﬁc run was not reported.
3.4.  The  relative  changes  in  protein  concentration  after
treatment  varied  between  the  platforms
Since the absolute protein concentration was not measured by
all platforms the relative difference in concentration between
the two time points was used to compare the performances
of the different platforms (Table 2). A mean fold change
greater than 1 corresponds to increased mean concentration
after TKI treatment and a mean fold change of less than
1 corresponds to decreased concentration after TKI treat-
ment. For the analytes IL-8, IL-6, VEGF and sE-selectin, a
decrease in mean concentration after treatment was mea-
sured by all platforms measuring these analytes. For the
analytes MMP-3 and PDGF-BB, an increase in mean concen-
tration after treatment was seen with all methods. ELISA
and Myriad RBM detected an increase in IFN concentra-
tion after treatment while BioPlex, Meso Scale Discovery and
Somalogic all detected decreasing levels. For MCP-1, all plat-
forms but Somalogic detected increased concentrations with
treatment. Myriad RBM detected an increase in sCD40L after
treatment while Somalogic detected a decrease. In Fig. 1, fold
changes after TKI treatment measured by the different plat-
forms are shown for the individual patients. For MCP-1, VEGF
and sE-selectin (Fig. 1B, E and F) all platforms measuring the-
ses analytes detected similar fold changes. For other analytes
such as IFN, IL-8, IL-6 and sCD40L (Fig. 1A, C, D and H) there
was a large variation in fold changes measured. For IL-8 the
median fold change was signiﬁcantly different when compar-
ing the Meso Scale Discovery and the Somalogic platforms. For
PDGF-BB the fold changes followed the same pattern in both
the BioPlex and the Somalogic platforms. The magnitudes of
the fold changes, however, were signiﬁcantly different (Fig. 1I).
In the Somalogic platform 430 (38%) of the proteins were sig-
niﬁcantly different expressed between the two  time points,
only two of these proteins displayed elevated levels after treat-
ment (data not shown). A company representative informed us
that this high number of proteins with decreased concentra-
tion may be due to unspeciﬁc binding in samples taken before
treatment.
3.5.  Relative  differences  in  protein  concentrations
correlated  between  the  different  platforms  for  some
analytesDirect correlations between relative differences in protein
concentration measured on different platforms were made to
investigate if an increase/decrease in one method gave the
same result in another method (Figs. 2 and 3). The relative
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Fig. 1 – Relative differences in protein concentrations of individual patients. The relative differences in protein concentration
were calculated as described in Section 2. The relative differences measured by the various platforms for the individual
patients are shown. Dots below the dotted line indicate a decrease in concentration after treatment and dots above the
dotted line symbolize an increase after treatment. The different platforms are represented by a distinct shape. Relative
differences for the proteins IFN (A), MCP-1 (B), IL-8 (C), IL-6 (D), VEGF (E), sE-selectin (F), MMP-3 (G), sCD40L (H), PDGF-BB (I)
are shown.
42  e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 37–47
Table 1 – Brief description of the various platforms tested.
ELISA BioPlex Meso Scale Discovery Myriad RBM Somalogic
Speciﬁcity Cross-reactivity
has been tested
for various
recombinant
cytokines/chemokines
Speciﬁcity has
been tested,
however, no
information
about which
analytes that
have been tested
is available
No
information
Validation  has
been performed
as deﬁned by
principles by the
Clinical
Laboratory
Standards
Institute (USA)
No  information
Simplicity Protocol was
easy to follow
Partly confusing
protocol
Protocol was
easy to follow
Instructions were
easy to follow
Instuctions were
easy to follow
No. of analytes analyzed 1/kit 27 9 44 1129
Cost (USD)/kit 560a 6700a 1728a 5940b 31000b
Cost (USD)/data point 9.00 4.00 3.10 4.35 0.89
Time ca 6 h/kit ca 1 working day ca 7 h 24 days from
sending samples
to receiving
report
38  days from
sending samples
to receiving ﬁrst
results
In house/Service In house In house In house Service Servicea Costs for personnel and analysis equipment not included.
b Freight not included.
difference in MCP-1 concentration was signiﬁcantly correlated
in all methods that measured this analyte (Fig. 2A). Also the
relative differences in sE-selectin (Fig. 2B) and MMP-3 (Fig. 2C)
concentrations measured by Myriad RBM correlated to the
differences measured on the Somalogic platform. Relative
PDGF-BB concentration differences measured by Somalogic
correlated to the differences measured by BioPlex (Fig. 2D).
For VEGF the relative differences correlated signiﬁcantly when
measured by Somalogic and Myriad RBM but not when Myriad
RBM was compared to BioPlex measurements (Fig. 3A). The
IL-8 relative difference in concentration measured by Meso
Fig. 2 – Correlations of relative differences between different plat
measured by four different platforms. (B and C) Correlation of rel
concentration measured by Somalogic and Myriad RBM. (D) Corr
measured by Somalogic and BioPlex. Statistically signiﬁcant corr
Spearman correlation. Spearman r-value and p-values are indicaScale Discovery did not correlate to the difference measured by
BioPlex or Somalogic (Fig. 3B). Spearman r-values and p-values
are indicated in respective graph.
3.6.  Absolute  protein  concentration  differed  between
the platformsThe BioPlex, ELISA, Meso Scale Discovery and Myriad RBM
platforms all determined the absolute concentration of an
analyte in a sample with help of standard curves. Hence, for
some of the analytes, the absolute concentration could be
forms. (A) Correlation of relative differences of MCP-1
ative differences in sE-selectin (B) and MMP-3 (C)
elation of relative differences in PDGF-BB concentration
elations were  determined with the non-parametric
ted in the graphs.
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Table 2 – Analyte characteristics for the different platforms analyzed.
Analyte Standard curve range Detectable
samples (%)
Mean fold
change
Max fold change Pooled CV (%)
IFN
BioPlex 1.87–30,646 pg/ml 100 0.99 2.25 11.53
ELISA 15.6–1000 pg/ml 14 1.47 1.49 2.81
Meso Scale Discovery 0.61–10,000 pg/ml 32 0.02 0.004 10.06
Myriad RBM Not provided 11 1.32 1.32 –
Somalogic No standard curve 100 0.70 1.22 –
MCP-1
BioPlex 1.45–23,735 pg/ml 96 1.24 6.28 7.02
ELISA 7.8–500 pg/ml 93 1.23 3.90 13.69
Myriad RBM Not provided 96 1.23 9.88 –
Somalogic No standard curve 100 0.82 1.80 –
IL-8
BioPlex 1.71–27,965 pg/ml 54 0.98 1.37 31.86
Meso Scale Discovery 0.61–10,000 pg/ml 100 0.18 4.13 11.92
Myriad RBM Not provided 29 0.95 1.00 –
Somalogic No standard curve 100 0.98 1.19 –
IL-6
BioPlex 1.18–19,412 pg/ml 43 0.93 1.21 9.15
Meso Scale Discovery 0.61–10,000 pg/ml 54 0.75 1.17 13.96
Myriad RBM Not provided 7 0.85 0.85 –
Somalogic No standard curve 100 0.47 1.00 –
VEGF
BioPlex 1.79–29,354 pg/ml 54 0.80 1.48 5.01
Myriad RBM Not provided 93 0.70 1.13 –
Somalogic No standard curve 100 0.86 1.29 –
sE-selectin
Myriad RBM Not provided 100 0.45 1.08 –
Somalogic No standard curve 100 0.50 1.36 –
MMP-3
Myriad RBM Not provided 100 1.28 2.16 –
Somalogic No standard curve 100 1.10 1.83 –
sCD40L
Myriad RBM Not provided 93 1.06 2.03 –
Somalogic No standard curve 100 0.80 1.17 –
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BioPlex 1.56–25,637 pg/ml 1
Somalogic No standard curve 1
ompared between the platforms. The concentration mea-
ured by one platform did not correspond to the concentration
easured by all other platforms for any of the analytes
nvestigated (Fig. 4). For MCP-1 similar patterns of protein
oncentration was seen after measurement by the three dif-
erent methods. In the ELISA and Myriad RBM methods, the
oncentrations measured were in about the same range with
xception of a few samples. The concentrations measured by
he BioPlex platform were lower than the concentrations mea-
ured by the two other platforms (Fig. 4B). IL-8 was detected
n all samples on the Meso Scale Discovery platform, but
nly in a few samples on the BioPlex and Myriad RBM plat-
orms. The concentrations, however, were higher in most of
he detected samples of the BioPlex and Myriad RBM plat-
orms (Fig. 4C). Both Meso Scale Discovery and Myriad RBM
easured very high concentrations of IL-6 in samples fromne patient both before and after treatment. The BioPlex
ethod did not detect high levels of IL-6 in the same samples
Fig. 4D).2.16 13.71 6.53
1.61 5.00 –
3.7.  Unspeciﬁc  binding  of  protein  in  chicken  plasma
To compare the amount of unspeciﬁc binding to proteins
present in plasma from other species, a chicken plasma sam-
ple was run on all platforms. To be able to compare the amount
of protein measured in chicken plasma by the different plat-
forms, protein concentration in chicken plasma was divided
with the concentration measured in the patient sample with
lowest detected concentration for the speciﬁc analyte. As seen
in Fig. 5, BioPlex (Fig. 5A), ELISA (Fig. 5B), Myriad RBM (Fig. 5C)
and Somalogic (Fig. 5D) all measured concentrations of at least
one analyte in the chicken plasma. In the BioPlex assay the
concentration of 18.5% (5/27) of the analytes were higher in
the chicken plasma than in the sample with lowest detected
concentration of that speciﬁc analyte (ratio > 1). Correspond-
ing values for ELISA and Somalogic were 100% (2/2) and 76%
(858/1129), respectively. The Somalogic platform detected con-
centrations of analytes in chicken plasma that was more  than
ten times higher than the lowest detected concentration in a
44  e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 37–47
Fig. 3 – Correlating and non-correlating relative differences on different platforms. Correlation of relative VEGF (A) and IL-8
(B) differences on different platforms. Statistically signiﬁcant correlation was determined with the non-parametric
dicatSpearman correlation. Spearman r-value and p-value are in
sample (ratio > 10) for 27.6% (312/1129) of the analytes (Fig. 5D),
a ratio higher than ten was not seen for any of the other plat-
forms. Meso Scale Discovery did not detect concentration in
chicken plasma of any of the analytes investigated on this
platform.
4.  Discussion
Multiplex techniques are widely used and are becoming
increasingly popular for the quantiﬁcation of proteins in
human plasma as a small amount of sample can result in a
great number of analytes analyzed. The challenge with mul-
tiplex assays is that targets with various properties should be
recognized in the same assay. In contrast, singleplex assays
buffers and other reagents can be speciﬁcally tailored to
detect a single target. Moreover, when the numbers of targets
increase, the risk of unspeciﬁcity increases. Hence, to be able
to compare protein quantiﬁcation data obtained by different
multiplex platforms, the platforms must be compared with
respect to accuracy, sensitivity and robustness. Various stud-
ies have compared two or more  multiplex methods for protein
quantiﬁcation [12–17].ed in the graph.
The present study aimed at comparing multiplex assays
performed in our laboratory with assays performed at com-
panies offering multiplex services through analysis of the
same patient plasma samples pre- and post-therapy. The
platforms compared have different characteristics and would
probably be used for different applications. One apparent
difference is the detection reagent. BioPlex, ELISA, Meso
Scale Discovery and Myriad RBM are all using antibodies to
detect proteins while the Somalogic platform uses modiﬁed
aptamers as binders of the proteins to detect. Aptamers are
binders reported to have many  advantages compared to anti-
bodies [18]. In our study, however, a high background was
seen when samples taken before TKI treatment were ana-
lyzed by the Somalogic platform. The samples analyzed were
from patient with CML before therapy, i.e. patients with a
high tumor-burden in their blood. It is possible that the high
tumor burden leads to an increase in protein content and/or
secretion of “sticky” products into plasma which could lead to
unspeciﬁc interactions with the SOMAmers. The high back-
ground in pre-treatment samples resulting in a decrease in
protein concentration in most post-treatment samples was
not seen in any of the other platforms. Moreover, higher back-
ground was also seen in chicken plasma when using the
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Fig. 4 – Comparison of absolute concentrations of various analytes measured on different platforms. The absolute
concentration of IFN (A), MCP-1 (B), IL-8 (C), IL-6 (D) and VEGF (E) as measured by different platforms at baseline (time point
A) and after three months of treatment (time point B). Each platform is represented by a distinct shape. Only samples with
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toncentrations above detection limit are shown in the ﬁgure
omalogic platform, compared to the other platforms, further
ndicating unspeciﬁcity in the assay. It should be noted that
he concentration of proteins in chicken plasma was related to
he concentration in the patient sample with lowest detected
oncentration. Hence, the difference calculated depends on
he concentration of analyte in the patient samples. The data
enerated from the pre- and post therapy patient material
n the Somalogic platform stresses the fact that the user,
nd the companies providing the platforms, must increase
heir knowledge in how different diseases may inﬂuence assayresults. The provider could possibly validate the assays using
patient material or at least inform the user of problems that
may arise when using complex human material.
Since not all platforms investigated measured absolute
protein concentration, the relative change in protein concen-
tration between the two sampling time points was used for
comparison. Analytes that had detectable levels of protein in
more  than one platform were compared. The sensitivity of
the different assays varied and this was most apparent when
investigating IFN, IL-8 and IL-6. The BioPlex assay measured
46  e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 37–47
Fig. 5 – Detection of protein in chicken plasma. The amount of protein binding in chicken plasma by the different platforms
was determined by calculating the ratio of the analyte amount detected in chicken plasma and the analyte amount detected
in the lowest detectable patient sample. The ratio is shown on the y-axis. Each bar on the x-axis represents one analyte that
was detected in the chicken plasma by the platform. For ticks on the x-axis without a bar, that analyte could not be detected
in the chicken plasma on that platform. Proteins detected in the chicken plasma are shown for BioPlex (A), ELISA (B), Myriad
RBM (C) and Somalogic (D).
IFN concentrations in all samples, while it was only detected
in a few samples in the ELISA and Meso Scale Discovery assays.
The ELISA is so far the golden standard for protein quan-
tiﬁcation, and the protocol only needs to be optimized with
respect to a very limited numbers of antibodies. If IFN con-
centration measured by ELISA was considered as the “true”
concentration, the BioPlex platform appeared to overestimate
the concentration for most samples. This may be because of
unspeciﬁc binding of antibodies.
The intra-assay accuracy was acceptable [19] (pooled
CV-values <15%) for all but three analytes where CV-values
could be calculated. In our study no inter-assay CV-values
were determined since every assay was run only ones. Oth-
ers, however, have reported lot dependent differences for the
BioPlex kit [14].
Even though the mean fold change in concentration as well
as the absolute concentration varied among different plat-
forms in our study, the fold changes for some of the analytes
correlated between some platforms. This has also been shown
by others comparing multiplex platforms with other multi- or
singleplex platforms [12,13,20]. Different multiplex methods
use different antibodies for protein detection, and the pro-
teins used for the creation of a standard curve can also varybetween the platforms. This may be one reason for obtain-
ing different absolute concentrations but similar fold changes
when measuring the same analyte by different platforms.
5.  Conclusions
Taken together, our results show that absolute concentrations
measured by different multiplex platforms and/or labora-
tories should be compared with caution and controls with
known concentrations not provided by the assay manufac-
turer should be run among the samples to ensure appropriate
concentration measurements. Which multiplex assay to use
should be chosen depending on application and the demands
on the assay. The relative concentrations can be compared
for some of the analytes measured by some of the platforms.
Before performing protein concentration comparison stud-
ies, such as comparing certain analytes in patients included
in different clinical trials, thorough validation [21] of the
assay should be performed to assure that the results are
truly comparable. Lastly, users as well as platform providers
must be cautious about the choice of platform when evaluat-
ing invaluable patient-derived material. Preferably, pre- and
m i c s
p
s
t
p
p
C
T
L
a
r
d
p
A
T
R
re u  p a o p e n p r o t e o 
ost-therapy samples should be assessed with or without
piked proteins on a variety of different platforms before hand
o ensure that the disease stage does not bias the results. The
re-screening validation should then lead to the ﬁnal choice of
latform for screening of the complete set of patient material.
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